文献速递心境障碍

斯坦福神经调控疗法治疗难治性抑郁的神经生理特征

Neurophysiological signatures of Stanford Neuromodulation Therapy in treatment resistant depression.
PubMed 文献 · Mol Psychiatry · 2026-09-02

该双盲随机假对照试验在24例难治性抑郁患者中利用纵向TMS-EEG探究SNT的神经生理机制。活性SNT从第3天起在治疗位点左背外侧前额叶逐步降低皮层兴奋性,并选择性降低估算的sgACC源活动且持续至1个月随访。探索性分析中基线sgACC活动较高与临床改善更大相关(r=-0.67;P=0.023),但需更大样本验证。

要点

  • 活性SNT从第3天起在左背外侧前额叶早期窗口成分降低27.9%(P<0.01),顶点对照位点无变化。
  • SNT选择性降低估算的sgACC源活动(F₁₃,₂₂₂=4.93;P<0.001),效应持续至1个月随访。
  • 探索性分析中基线sgACC活动较高与临床改善更大相关(r=-0.67;P=0.023),尚需验证。

核心结论

  • SNT诱导渐进性、位点特异的皮层调控,并对估算的sgACC源活动产生选择性下游效应。
  • 早期皮层兴奋性变化是SNT应答的候选神经生理标志物。
  • 基线sgACC活动与临床结局的关联为初步发现,需在更大样本中前瞻性验证其预测效用。

研究设计与样本

  • 斯坦福大学2017-2018年开展的双盲随机假对照试验,分析时间为2024年8月至2025年10月。
  • 纳入24例TMS初治的难治性抑郁患者(MADRS≥20;至少1种抗抑郁药治疗失败)。
  • 随机分为活性SNT组(n=12)与假SNT组(n=12),靶点为左背外侧前额叶。
  • SNT方案为连续5天每天10次,共90,000脉冲;共进行14次TMS-EEG采集。

主要发现

  • 活性SNT在治疗位点逐步降低皮层兴奋性,第3天早期窗口成分显著下降27.9%(P<0.01)。
  • 顶点对照位点未见变化;位点特异比较证实早期窗口降低仅见于左背外侧前额叶(t₂₂=-3.82;P<0.001)。
  • SNT选择性降低估算的sgACC源活动(F₁₃,₂₂₂=4.93;P<0.001),效应持续至1个月随访。
  • 活性组探索性分析中,基线估算sgACC源活动较高与临床改善更大相关(r=-0.67;P=0.023)。

关键数值与推荐

  • 难治性抑郁定义:MADRS≥20且至少1种抗抑郁药治疗失败。
  • SNT方案:连续5天每天10次,靶向左背外侧前额叶,共90,000脉冲。

临床怎么用

  • SNT的早期皮层兴奋性变化可作为监测治疗应答的候选神经生理标志物。
  • 基线sgACC源活动可能提示临床改善程度,但目前仅属探索性发现,不宜用于临床预测。

局限性

  • 基线sgACC活动与临床结局的关联为探索性分析,样本量小(活性组n=12),需更大样本重复验证。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment-resistant depression (TRD) affects approximately 30% of patients with major depressive disorder. Stanford Neuromodulation Therapy (SNT), a high-dose intermittent theta-burst transcranial magnetic stimulation protocol, produces rapid antidepressant effects, but its neurophysiological mechanisms remain unclear. Here, we used longitudinal TMS-EEG to characterize the progressive neurophysiological changes induced by SNT, assess their site-specificity, and explore whether baseline neural markers are associated with clinical response. We conducted a double-blind, randomized, sham-controlled trial at Stanford University (2017-2018; analysis August 2024-October 2025) in 24 TMS-naïve participants with TRD (Montgomery-Åsberg Depression Rating Scale ≥20; ≥1 failed antidepressant trial). Participants were randomized to active (n = 12) or sham (n = 12) SNT, consisting of 10 sessions per day over 5 consecutive days targeting the left dorsolateral prefrontal cortex (90,000 pulses). TMS-EEG was acquired at two baseline sessions, before and after each treatment session, and at 1-month follow-up (14 TMS-EEG sessions in total). Active SNT progressively reduced cortical excitability at the treatment site, with significant decreases by day 3 in the early window component (-27.9%; P < 0.01), while no changes were observed at the vertex control site. Site-specific comparisons confirmed early window reductions only at the left dorsolateral prefrontal cortex (t₂₂ = -3.82; P < 0.001). SNT also selectively decreased estimated medial prefrontal source activity consistent with the subgenual anterior cingulate cortex (sgACC) across sessions (F₁₃,₂₂₂ = 4.93; P < 0.001), with effects persisting at 1-month follow-up. In an exploratory analysis in the active group (n = 12), higher baseline estimated sgACC source activity was associated with greater clinical improvement (r = -0.67; P = 0.023); although promising, the latter preliminary finding requires replication in larger, adequately powered samples before predictive utility can be established. These findings indicate that SNT induces progressive, site-specific cortical modulation and selective downstream effects on estimated sgACC source activity. Early cortical excitability changes represent candidate neurophysiological markers of SNT response, while the observed association between baseline sgACC activity and clinical outcome, while preliminary, motivates prospective investigation of subcortical source activity as a potential predictor of treatment response in larger trials. ClinicalTrials.gov Identifier: NCT03068715.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Momi D, Buchanan DM, Wada M, et al. Neurophysiological signatures of Stanford Neuromodulation Therapy in treatment resistant depression. Mol Psychiatry. 2026. PMID: 42686996. doi:10.1038/s41380-026-03837-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。